Circulating IL‐6‐type cytokines and sIL‐6R in patients with multiple myeloma

No abstract is available for this paper.

• Publication year

  1999

• Venue

  British Journal of Haematology

• Publication date

  1999-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.1999.01350.xPMID 10233412
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.

  1998cited by this paper
• The prognostic value of soluble interleukin‐6 receptor in patients with multiple myeloma

  1998cited by this paper
• Serum oncostatin M in multiple myeloma: association with prognostic factors

  1997cited by this paper
• Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus.

  1997cited by this paper
• A ciliary neurotrophic factor-sensitive human myeloma cell line.

  1996cited by this paper
• Soluble interleukin‐6 receptor (sIL‐6R), a new prognostic factor in multiple myeloma

  1996cited by this paper
• Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.

  1996cited by this paper
• Soluble interleukin‐6 receptor as a prognostic factor in multiple myeloma

  1996cited by this paper
• Tumour necrosis factor α (TNF-α), interleukin-6 (IL-6) and their soluble receptors (sTNF-α-Rp55 and slL-6R) serum levels in systemic lupus erythematodes

  1996cited by this paper
• Serum interleukin‐6 (IL‐6) and interleukin‐4 (IL‐4) in patients with multiple myeloma (MM)

  1996cited by this paper
• Cytokine signal transduction.

  1995cited by this paper
• Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma.

  1995cited by this paper
• Clinical significance of elevated soluble interleukin‐6 receptor levels in the sera of patients with plasma cell dyscrasias

  1995cited by this paper
• Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders.

  1995cited by this paper
• Interleukin-6 inhibits apoptosis of malignant plasma cells.

  1995cited by this paper
• Interleukin-6 family of cytokines and gp130.

  1995cited by this paper
• Interleukin‐10 induces interleukin‐11 responsiveness in human myeloma cell lines

  1995cited by this paper
• Interleukin-6 in human multiple myeloma.

  1995cited by this paper
• Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice.

  1994cited by this paper
• Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130

  1994cited by this paper
• Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130

  1994cited by this paper
• Hematopathology of interleukin 6-type cytokines.

  1994cited by this paper
• Cytokine signal transduction.

  1994cited by this paper
• Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.

  1994cited by this paper
• Determination of IL6, IL1, and IL4 in the plasma of patients with multiple myeloma.

  1994cited by this paper
• A highly sensitive quantitative bioassay for human interleukin-11.

  1994cited by this paper
• Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy

  1993cited by this paper
• Mechanisms of bone lesions in multiple myeloma.

  1992cited by this paper
• Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130.

  1992cited by this paper
• Interleukin-6 and its receptor: a paradigm for cytokines.

  1992cited by this paper
• Cytokine network in human multiple myeloma.

  1992cited by this paper
• Interleukin-6 is a prognostic factor in multiple myeloma.

  1991cited by this paper
• Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]

  1991cited by this paper
• Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease.

  1991cited by this paper
• Acute‐phase response of human hepatocytes: Regulation of acute‐phase protein synthesis by interleukin‐6

  1990cited by this paper
• Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

  1989cited by this paper
• Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

  1989cited by this paper
• Purification, cloning, and expression of ciliary neurotrophic factor (CNTF).

  1989cited by this paper
• Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

  1989influential reference
• Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.

  1989cited by this paper
• Recombinant human interleukin‐6 (IL‐6/BSF‐2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes

  1988cited by this paper
• Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

  1988cited by this paper
• Staging and kinetics of multiple myeloma.

  1982cited by this paper
• A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

  1975cited by this paper
• Research Paper Mediators of Inflammation, 7, 347–353 (1998)

  year unknowncited by this paper

• Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma

  2020cites this paper
• Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity

  2020cites this paper
• CMAR_A_230386 10623..10632

  2019cites this paper
• High Inflammatory Factor Grading Predicts Poor Disease-Free Survival in AJCC Stage I-II Hepatocellular Carcinoma Patients After R0 Resection

  2019cites this paper
• Oncostatin M: Potential Implications for Malignancy and Metabolism.

  2017cites this paper
• Neurotrophic factors and their inhibitors in chronic pain treatment.

  2017cites this paper
• Monitoring Disease Status in Multiple Myeloma in View of Proliferation-leading Cytokines

  2017cites this paper
• The Biological Effects of Interleukin-6 and Their Clinical Applications in Autoimmune Diseases and Cancers

  2017cites this paper
• Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth

  2017cites this paper
• Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

  2016cites this paper
• Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.

  2016cites this paper
• Additive/Synergistic Effects of Interleukin-6 and Interleukin-10 on the Proliferation of Human Myeloma Cells

  2015cites this paper
• Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma

  2015cites this paper
• Relevanz der konstitutiven Aktivierung des IL-6-Signalwegs für die Proliferation und Transformation humaner Leberzellen

  2014cites this paper
• Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma

  2013cites this paper
• Soluble Interleukin-6 Receptor is a Prognostic Marker for Relapse-Free Survival in Estrogen Receptor-Positive Breast Cancer

  2013cites this paper
• A Role for Orexin Neuron Activity in Cytotoxic Chemotherapy-Induced Fatigue

  2013cites this paper
• The Role of Chronic Inflammation in Obesity-Associated Cancers

  2013cites this paper
• In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.

  2012cites this paper
• The Effects of Viscum album (Mistletoe) QuFrF Extract and Vincristine in Human Multiple Myeloma Cell Lines - A Comparative Experimental Study Using Several and Different Parameters

  2012cites this paper
• Blockade of interleukin‐6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

  2011cites this paper
• Mechanisms Inducing Low Bone Density in Duchenne Muscular Dystrophy in Mice and Humans

  2011cites this paper
• Molecular Mechanisms of Obesity, Inflammation and Cancer: The Use of in vitro Model Approaches for Targeted Prevention Strategies

  2010cites this paper
• Thrombopoietic cytokine and P-selectin levels in patients with multiple myeloma undergoing autologous stem cell transplantation: decrease in posttransplantation P-selectin levels might predict the degree of maximum response.

  2009cites this paper
• Simultaneous Analysis of Cytokines and Costimulatory Molecules Concentrations by ELISA Technique and of Probabilities of Measurable Concentrations of Interleukins IL-2, IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-13 Occurring in Plasma of Healthy Blood Donors

  2006cites this paper
• Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus

  2006cites this paper
• Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

  2006cites this paper
• Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons.

  2005cites this paper
• PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells

  2004cites this paper
• Treatment of Multiple Myeloma with All-Trans Retinoic Acid Alone and in Combination with Chemotherapy: a Phase I/II Trial

  2004cites this paper
• Ciliary neurotrophic factor preferentially enhances spontaneous IgE production by B cells from atopic patients.

  2004cites this paper
• CNTF, a pleiotropic cytokine: emphasis on its myotrophic role.

  2004cites this paper
• Multiple myeloma presenting as fever of unknown origin.

  2003cites this paper
• How does interleukin-6 affect the membrane expressions of interleukin-6 receptor and gp130 and the proliferation of the human myeloma cell line OPM-2?

  2003cites this paper
• Circulating angiogenic cytokines in multiple myeloma and related disorders.

  2003cites this paper
• Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

  2003cites this paper
• High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.

  2003cites this paper
• Effect of Interleukin 6 on the Hepatic Metabolism of Itraconazole and Its Metabolite Hydroxyitraconazole Using Primary Human Hepatocytes

  2003cites this paper
• Myélome multiple: Physiopathologie

  2003cites this paper
• Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.

  2003cites this paper
• Mieloma múltiple: Fisiopatología

  2003cites this paper
• Pediatrician Prescription

  2002cites this paper
• Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.

  2002cites this paper
• Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affect these parameters?

  2002cites this paper
• Interleukin‐6 in combination with its soluble IL‐6 receptor sensitises rat skin nociceptors to heat, in vivo

  2002cites this paper
• Autocrine Production and Synergistic Growth-Promoting Activity of Interleukin-6 and Oncostatin M in a New Human Myeloma Cell Line TU-1

  2002cites this paper
• Circulating IL‐6 and sIL‐6R in Patients with Hepatocellular Carcinoma

  2002cites this paper
• Widespread Bone Disease in Acute Myeloid Leukaemia

  2001cites this paper
• Interleukin-6 Regulation of the Human DNA Methyltransferase (HDNMT) Gene in Human Erythroleukemia Cells*

  2001cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2001cites this paper
• Interleukin 6, tumour necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma

  2000cites this paper
• Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.

  2000cites this paper
• Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma.

  2000cites this paper
• A model that reproduces syndromes associated with human multiple myeloma in nonirradiated SCID mice.

  2000cites this paper
• The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells.

  2000cites this paper
• Anti-inflammatory gp 130-mediated signalling as a therapeutic target

  2000influential citation
• Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis

  2000cites this paper
• gp130-mediated signalling as a therapeutic target

  2000influential citation
• A Model that Reproduces Syndromes Associated with Human Multiple Myeloma in Nonirradiated SCID Mice (44479)

  2000cites this paper
• Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.

  1999cites this paper